Literature DB >> 3520132

Minoxidil and captopril in severe hypertension.

P Greminger, E Foerster, H Vetter, P Baumgart, W Vetter.   

Abstract

The antihypertensive efficacy of minoxidil and captopril was compared in 23 males with essential or renal parenchymatous hypertension refractory to conventional antihypertensive drug therapy. Following a pretreatment period the patients were randomly assigned to receive either minoxidil, 2.5 mg twice daily (n = 12), or captopril, 25 mg twice daily (n = 11). In patients with diastolic blood pressure greater than 95 mmHg, doses of minoxidil and captopril were increased in 2-week intervals. Patients who maintained diastolic pressure greater than 95 mmHg and/or those with intolerable side effects were switched over to the alternative substance. After a mean observation period of 12 weeks a significant decrease in systolic and diastolic blood pressure was observed (179/114 vs 148/92 mmHg in the minoxidil group; 176/111 vs 158/97 mmHg in the captopril group). The primary response rate was 75% in patients treated with minoxidil and 55% in those with captopril (not significant). After the change to the alternative substance two of the four non-responders on captopril and one of the two non-responders on minoxidil became responders. Side effects occurred significantly more often during minoxidil than captopril (p less than 0.05). The high efficacy of minoxidil and captopril in the treatment of severe hypertension refractory to conventional drugs was confirmed. Minoxidil lowered blood pressure slightly more than captopril, but it had a higher incidence of side effects than captopril.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3520132     DOI: 10.1007/bf01711952

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  27 in total

Review 1.  Minoxidil therapy in refractory hypertension analysis of 155 patients.

Authors:  G W Keusch; P Weidmann; V Campese; D B Lee; A T Upham; S G Massry
Journal:  Nephron       Date:  1978       Impact factor: 2.847

2.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

3.  Minoxidil--an alternative to nephrectomy for refractory hypertension.

Authors:  W A Pettinger; H C Mitchell
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

4.  Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone.

Authors:  W Vetter; H Vetter; W Siegenthaler
Journal:  Acta Endocrinol (Copenh)       Date:  1973-11

Review 5.  Angiotensin-converting enzyme inhibitors: past, present, and bright future.

Authors:  C R Edwards; P L Padfield
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

Review 6.  Minoxidil.

Authors:  B Canaday
Journal:  South Med J       Date:  1980-01       Impact factor: 0.954

7.  Clinical use of an orally acting converting enzyme inhibitor: captopril.

Authors:  H R Brunner; H Gavras; B Waeber; S C Textor; G A Turini; J P Wauters
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

8.  Effect of minoxidil on blood pressure and hemodynamics in severe hypertension.

Authors:  R K Bryan; S W Hoobler; J Rosenzweig; J M Weller; J M Purdy
Journal:  Am J Cardiol       Date:  1977-05-26       Impact factor: 2.778

9.  Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril.

Authors:  D B Case; S A Atlas; P A Sullivan; J H Laragh
Journal:  Circulation       Date:  1981-10       Impact factor: 29.690

Review 10.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

View more
  4 in total

Review 1.  Intellectual property law: a primer for scientists.

Authors:  William M Brown
Journal:  Mol Biotechnol       Date:  2003-03       Impact factor: 2.695

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Drug repositioning based on individual bi-random walks on a heterogeneous network.

Authors:  Yuehui Wang; Maozu Guo; Yazhou Ren; Lianyin Jia; Guoxian Yu
Journal:  BMC Bioinformatics       Date:  2019-12-24       Impact factor: 3.169

4.  Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis.

Authors:  Heiko M Mundt; Matthias Matenaer; Alexander Lammert; Uwe Göttmann; Bernhard K Krämer; Rainer Birck; Urs Benck
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-01       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.